Obesity and psychotic disorders: Uncovering common mechanisms through metabolomics

DMM Disease Models and Mechanisms

Volumn 5, Issue 5, 2012, Pages 614-620

  Orešič, Matej ^a  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ELOVL FATTY ACID ELONGASE 6; LIPIDOME; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME;

ALZHEIMER DISEASE; COMORBIDITY; DIABETES MELLITUS; HUMAN; LIPIDOMICS; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; METABOLOMICS; NOTE; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

BIOLOGICAL MARKERS; HUMANS; LIPID METABOLISM; METABOLIC DISEASES; METABOLOMICS; OBESITY; PSYCHOTIC DISORDERS;

EID: 84865498638     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.009845     Document Type: Note

References (69)

1. Arango, C., Bobes, J., Kirkpatrick, B., Garcia-Garcia, M. and Rejas, J. (2011). Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur. Neuropsychopharmacol. 21, 867-875.
2. Barr, J., Vázquez-Chantada, M., Alonso, C., Pérez- Cormenzana, M., Mayo, R., Galán, A., Caballería, J., Martín-Duce, A., Tran, A., Wagner, C. et al. (2010). Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9, 4501-4512.
3. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. and Erbaugh, J. (1961). An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571.
4. Catenacci, V. A., Hill, J. O. and Wyatt, H. R. (2009). The obesity epidemic. Clin. Chest Med. 30, 415-444.
5. Cohen, J. C., Horton, J. D. and Hobbs, H. H. (2011). Human fatty liver disease: old questions and new insights. Science 332, 1519-1523.
6. Correll, C. U., Kane, J. M. and Manu, P. (2011). Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 261, 417-423.
7. DiPatrizio, N. V. and Piomelli, D. (2012). The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci. 35, 403-411.
8. Fernø, J., Raeder, M. B., Vik-Mo, A. O., Skrede, S., Glambek, M., Tronstad, K. J., Breilid, H., Løvlie, R., Berge, R. K., Stansberg, C. et al. (2005). Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5, 298-304.
9. Fraguas, D., Merchán-Naranjo, J., Laita, P., Parellada, M., Moreno, D., Ruiz-Sancho, A., Cifuentes, A., Giráldez, M. and Arango, C. (2008). Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J. Clin. Psychiatry 69, 1166-1175.
10. Gall, W. E., Beebe, K., Lawton, K. A., Adam, K. P., Mitchell, M. W., Nakhle, P. J., Ryals, J. A., Milburn, M. V., Nannipieri, M., Camastra, S. et al. (2010). alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5, e10883.
11. Goodacre, R., Vaidyanathan, S., Dunn, W. B., Harrigan, G. G. and Kell, D. B. (2004). Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22, 245-252.
12. Guest, P. C., Wang, L., Harris, L. W., Burling, K., Levin, Y., Ernst, A., Wayland, M. T., Umrania, Y., Herberth, M., Koethe, D. et al. (2010). Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol. Psychiatry 15, 118-119.
13. Han, X., Holtzman, D. M. and McKeel, D. W., Jr (2001). Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77, 1168-1180.
14. Hansen, T., Ingason, A., Djurovic, S., Melle, I., Fenger, M., Gustafsson, O., Jakobsen, K. D., Rasmussen, H. B., Tosato, S., Rietschel, M. et al. (2011). At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol. Psychiatry 70, 59-63.
15. Henneman, D. H., Altschule, M. D. and Goncz, R. M. (1954). Carbohydrate metabolism in brain disease. II. Glucose metabolism in Schizophrenic, manicdepressive, and involutional psychoses. AMA Arch. Intern. Med. 94, 402-416.
16. Hilvo, M., Denkert, C., Lehtinen, L., Müller, B., Brockmöller, S., Seppänen-Laakso, T., Budczies, J., Bucher, E., Yetukuri, L., Castillo, S. et al. (2011). Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 71, 3236-3245.
17. Holmes, E., Tsang, T. M., Huang, J. T.-J., Leweke, F. M., Koethe, D., Gerth, C. W., Nolden, B. M., Gross, S., Schreiber, D., Nicholson, J. K. et al. (2006). Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3, e327.
18. Holmes, E., Loo, R. L., Stamler, J., Bictash, M., Yap, I. K., Chan, Q., Ebbels, T., De Iorio, M., Brown, I. J., Veselkov, K. A. et al. (2008). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453, 396-400.
19. Illig, T., Gieger, C., Zhai, G., Römisch-Margl, W., Wang-Sattler, R., Prehn, C., Altmaier, E., Kastenmüller, G., Kato, B. S., Mewes, H.-W. et al. (2010). A genomewide perspective of genetic variation in human metabolism. Nat. Genet. 42, 137-141.
20. Jung, K. M., Clapper, J. R., Fu, J., D'Agostino, G., Guijarro, A., Thongkham, D., Avanesian, A., Astarita, G., DiPatrizio, N. V., Frontini, A. et al. (2012). 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab. 15, 299-310.
21. Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M. and Krishnan, K. R. R. (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12, 934-945.
22. Kaidanovich-Beilin, O., Cha, D. S. and McIntyre, R. S. (2012). Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol. Rep. 4, 14.
23. Katajamaa, M. and Oresic, M. (2007). Data processing for mass spectrometry-based metabolomics. J. Chromatogr. A 1158, 318-328.
24. Kirkpatrick, B., Miller, B. J., Garcia-Rizo, C., Fernandez-Egea, E. and Bernardo, M. (2012). Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr. Bull. 38, 280-284.
25. Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E. L., Tuomilehto, J., Soininen, H. and Nissinen, A. (2005). Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62, 1556-1560.
26. Kotronen, A. and Yki-Järvinen, H. (2008). Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 27-38.
27. Kotronen, A., Seppänen-Laakso, T., Westerbacka, J., Kiviluoto, T., Arola, J., Ruskeepää, A. L., Oresic, M. and Yki-Järvinen, H. (2009a). Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 58, 203-208.
28. Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M. R., Oresic, M. and Yki-Järvinen, H. (2009b). Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52, 684-690.
29. Lichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F. and Hultman, C. M. (2009). Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373, 234-239.
30. Lusis, A. J. (2000). Atherosclerosis. Nature 407, 233-241.
31. Lusis, A. J., Attie, A. D. and Reue, K. (2008). Metabolic syndrome: from epidemiology to systems biology. Nat. Rev. Genet. 9, 819-830.
32. Maeba, R., Maeda, T., Kinoshita, M., Takao, K., Takenaka, H., Kusano, J., Yoshimura, N., Takeoka, Y., Yasuda, D., Okazaki, T. et al. (2007). Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J. Atheroscler. Thromb. 14, 12-18.
33. Maher, B. (2008). Personal genomes: The case of the missing heritability. Nature 456, 18-21.
34. Martin, F.-P. J., Dumas, M.-E., Wang, Y., Legido-Quigley, C., Yap, I. K. S., Tang, H., Zirah, S., Murphy, G. M., Cloarec, O., Lindon, J. C. et al. (2007). A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 3, 112.
35. Medina-Gomez, G., Gray, S. L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R. K., Jimenez-Linan, M., Blount, M., Yeo, G. S. et al. (2007). PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64.
36. Medina-Gomez, G., Yetukuri, L., Velagapudi, V., Campbell, M., Blount, M., Jimenez-Linan, M., Ros, M., Oresic, M. and Vidal-Puig, A. (2009). Adaptation and failure of pancreatic beta cells in murine models with different degrees of metabolic syndrome. Dis. Model. Mech. 2, 582-592.
37. Meyer-Lindenberg, A. and Weinberger, D. R. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 7, 818-827.
38. Møller, H., Mellemgaard, A., Lindvig, K. and Olsen, J. H. (1994). Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer 30, 344-350.
39. Mukherjee, S., Schnur, D. B. and Reddy, R. (1989). Family history of type 2 diabetes in schizophrenic patients. Lancet 333, 495.
40. Murphy, R. C. (2001). Free-radical-induced oxidation of arachidonoyl plasmalogen phospholipids: antioxidant mechanism and precursor pathway for bioactive eicosanoids. Chem. Res. Toxicol. 14, 463-472.
41. Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A. et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9, 311-326.
42. Nikkilä, J., Sysi-Aho, M., Ermolov, A., Seppänen-Laakso, T., Simell, O., Kaski, S. and Oresic, M. (2008). Gender-dependent progression of systemic metabolic states in early childhood. Mol. Syst. Biol. 4, 197.
43. Oresic, M., Vidal-Puig, A. and Hänninen, V. (2006). Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev. Mol. Diagn. 6, 575-585.
44. Oresic, M., Hänninen, V. A. and Vidal-Puig, A. (2008a). Lipidomics: a new window to biomedical frontiers. Trends Biotechnol. 26, 647-652.
45. Oresic, M., Simell, S., Sysi-Aho, M., Näntö-Salonen, K., Seppänen-Laakso, T., Parikka, V., Katajamaa, M., Hekkala, A., Mattila, I., Keskinen, P. et al. (2008b). Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J. Exp. Med. 205, 2975-2984.
46. Oresic, M., Hyötyläinen, T., Herukka, S.-K., Sysi-Aho, M., Mattila, I., Seppänan- Laakso, T., Julkunen, V., Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J. et al. (2011a). Metabolome in progression to Alzheimer's disease. Transl. Psychiatr. 1, e57.
47. Oresic, M., Tang, J., Seppänen-Laakso, T., Mattila, I., Saarni, S. E., Saarni, S. I., Lönnqvist, J., Sysi-Aho, M., Hyötyläinen, T., Perälä, J. et al. (2011b). Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 3, 19.
48. Oresic, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. et al. (2012). Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 4, 1.
49. Pauling, L., Robinson, A. B., Teranishi, R. and Cary, P. (1971). Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. USA 68, 2374-2376.
50. Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T. et al. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64, 19-28.
51. Pietiläinen, K. H., Naukkarinen, J., Rissanen, A., Saharinen, J., Ellonen, P., Keränen, H., Suomalainen, A., Götz, A., Suortti, T., Yki-Järvinen, H. et al. (2008). Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med. 5, e51.
52. Pietiläinen, K. H., Róg, T., Seppänen-Laakso, T., Virtue, S., Gopalacharyulu, P., Tang, J., Rodriguez-Cuenca, S., Maciejewski, A., Naukkarinen, J., Ruskeepää, A.- L. et al. (2011). Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biol. 9, e1000623.
53. Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J. and Sanyal, A. J. (2007). A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081-1090.
54. Rhee, E. P., Cheng, S., Larson, M. G., Walford, G. A., Lewis, G. D., McCabe, E., Yang, E., Farrell, L., Fox, C. S., O'Donnell, C. J. et al. (2011). Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121, 1402-1411.
55. Saarni, S. E., Saarni, S. I., Fogelholm, M., Heliövaara, M., Perälä, J., Suvisaari, J. and Lönnqvist, J. (2009). Body composition in psychotic disorders: a general population survey. Psychol. Med. 39, 801-810.
56. Schwarz, E., Prabakaran, S., Whitfield, P., Major, H., Leweke, F. M., Koethe, D., McKenna, P. and Bahn, S. (2008). High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J. Proteome Res. 7, 4266-4277.
57. Suvisaari, J. M., Haukka, J. K., Tanskanen, A. J. and Lönnqvist, J. K. (1999). Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch. Gen. Psychiatry 56, 733-740.
58. Suvisaari, J. M., Saarni, S. I., Perälä, J., Suvisaari, J. V., Härkänen, T., Lönnqvist, J. and Reunanen, A. (2007). Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J. Clin. Psychiatry 68, 1045-1055.
59. Tang, J., Tan, C. Y., Oresic, M. and Vidal-Puig, A. (2009). Integrating post-genomic approaches as a strategy to advance our understanding of health and disease. Genome Med. 1, 35.
60. Teffer, K. and Semendeferi, K. (2012). Human prefrontal cortex: evolution, development, and pathology. Prog. Brain Res. 195, 191-218.
61. Unger, R. H. (1997). How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol. Metab. 8, 276-282.
62. Van Gaal, L. F., Mertens, I. L. and De Block, C. E. (2006). Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880.
63. Velagapudi, V. R., Hezaveh, R., Reigstad, C. S., Gopalacharyulu, P. V., Yetukuri, L., Islam, S., Felin, J., Perkins, R., Borén, J., Oresic, M. et al. (2010). The gut microbiota modulates host energy and lipid metabolism in mice. J. Lipid Res. 51, 1101-1112.
64. Virtue, S. and Vidal-Puig, A. (2008). It's not how fat you are, it's what you do with it that counts. PLoS Biol. 6, e237.
65. Virtue, S. and Vidal-Puig, A. (2010). Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome - an allostatic perspective. Biochim. Biophys. Acta 1801, 338-349.
66. Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C. et al. (2011). Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448-453.
67. Westerbacka, J., Kotronen, A., Fielding, B. A., Wahren, J., Hodson, L., Perttilä, J., Seppänen-Laakso, T., Suortti, T., Arola, J., Hultcrantz, R. et al. (2010). Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology 139, 1961-1971.e1.
68. Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., Cao, Y., Wang, X., Qiu, Y., Su, M. et al. (2011). Potential metabolite markers of schizophrenia. Mol. Psychiatry [Epub ahead of print] doi: 10.1038/mp.2011.131.
69. Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H. and Srishord, M. (2011). Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 9, 524-530.